BioCentury
ARTICLE | Clinical News

GPI-0100: Phase I data

February 28, 2005 8:00 AM UTC

In a dose-escalation, U.S. Phase I trial in 42 evaluable patients with relapsed prostate cancer, GPI-0100 used in combination with a bivalent vaccine was well tolerated and led to a dose-dependent enh...